Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer.

[1]  T. Mukohara,et al.  Abstract P5-02-42: Soluble CD163 may be a predictive biomarker of the efficacy of nivolumab plus chemotherapy in patients with HER2-negative metastatic breast cancer (WJOG9917BTR) , 2023, Cancer Research.

[2]  A. Schneeweiss,et al.  Abstract PD9-04: Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients , 2023, Cancer Research.

[3]  L. Wessels,et al.  IL-5-producing CD4+ T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. , 2022, Cancer cell.

[4]  L. Dercle,et al.  Rationale for LDH-targeted cancer immunotherapy. , 2022, European journal of cancer.

[5]  G. Viale,et al.  Neoadjuvant immunotherapy in TNBC: lesson learnt, remaining questions. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  M. Rothenberg,et al.  Eosinophil–lymphocyte interactions in the tumor microenvironment and cancer immunotherapy , 2022, Nature Immunology.

[7]  C. Denkert,et al.  Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  S. Loi,et al.  Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. , 2022, The New England journal of medicine.

[9]  A. Schneeweiss,et al.  Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer. , 2022, Journal of Clinical Oncology.

[10]  A. Glas,et al.  The ImPrint immune signature to identify patients with high-risk early breast cancer who may benefit from PD1 checkpoint inhibition in I-SPY2. , 2022, Journal of Clinical Oncology.

[11]  Rosalyn W. Sayaman,et al.  Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. , 2022, Cancer cell.

[12]  C. Criscitiello,et al.  Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives , 2022, Cancers.

[13]  H. Rugo,et al.  Immunotherapy for early triple negative breast cancer: research agenda for the next decade , 2022, NPJ breast cancer.

[14]  E. Winer,et al.  Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC) , 2022, Cancer Research.

[15]  R. Greil,et al.  Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial , 2022, Cancer Research.

[16]  R. Greil,et al.  Abstract GS1-00: Single-cell spatial analysis by imaging mass cytometry and immunotherapy response in triple-negative breast cancer (TNBC) in the NeoTRIPaPDL1 trial , 2022, Cancer Research.

[17]  P. Fasching,et al.  Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. , 2022, The New England journal of medicine.

[18]  T. Al-Tweigeri,et al.  Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer. , 2022, Immunotherapy.

[19]  L. Gianni,et al.  Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.

[20]  Xueda Hu,et al.  Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. , 2021, Cancer cell.

[21]  L. Pusztai,et al.  A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer , 2021, Cancers.

[22]  D. Ajarim,et al.  Weekly Paclitaxel given concurrently with Durvalumab has a favorable safety profile in triple-negative metastatic breast cancer , 2021, Scientific Reports.

[23]  M. Timmermans,et al.  Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer , 2021, Nature Communications.

[24]  B. Győrffy,et al.  LBA12 Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial , 2021, Annals of Oncology.

[25]  A. Schneeweiss,et al.  First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  E. Petricoin,et al.  Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti–PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer , 2021, Clinical Cancer Research.

[27]  Y. She,et al.  The detection value of PD-L1 expression in biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis , 2021, Journal of thoracic disease.

[28]  Y. Wang,et al.  Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Anh Nguyen-Duc,et al.  PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer , 2021, Journal of the National Cancer Institute.

[30]  Leonard D. Goldstein,et al.  The tumor microenvironment (TME) and atezolizumab + nab-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130. , 2021 .

[31]  R. Schilsky,et al.  Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Spitzer,et al.  Systemic immunity in cancer , 2021, Nature Reviews Cancer.

[33]  E. Winer,et al.  Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[34]  B. Ring,et al.  A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies , 2021, Heliyon.

[35]  P. Fasching,et al.  Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer , 2021, Clinical Cancer Research.

[36]  L. Esserman,et al.  Abstract PD9-02: Personalized ctDNA as a predictive biomarker in high-risk early stage breast cancer (EBC) treated with neoadjuvant chemotherapy (NAC) with or without pembrolizumab (P) , 2021 .

[37]  E. Winer,et al.  Abstract PD14-07: Association between biomarkers and response to pembrolizumab in patients with metastatic triple-negative breast cancer (mTNBC): Exploratory analysis from KEYNOTE-086 , 2021 .

[38]  I. Wistuba,et al.  PD-L1 as a biomarker of response to immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.

[39]  V. Seshan,et al.  Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors , 2021, Nature Communications.

[40]  Anh Nguyen-Duc,et al.  Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study , 2021, Journal of the National Cancer Institute.

[41]  Cailin E. Joyce,et al.  Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor , 2021, Oncogene.

[42]  T. Pugh,et al.  Applications of Circulating Tumor DNA in a Cohort of Phase I Solid Tumor Patients Treated With Immunotherapy , 2021, JNCI cancer spectrum.

[43]  P. Van Loo,et al.  Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.

[44]  I. Bièche,et al.  Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial , 2021, Nature Medicine.

[45]  Ahn， Jin Hee,et al.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.

[46]  J. Reis-Filho,et al.  Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy , 2020, Nature Cancer.

[47]  M. Khasraw,et al.  Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better? , 2020, Clinical Cancer Research.

[48]  Hong Zhang,et al.  Is sCD163 a Clinical Significant Prognostic Value in Cancers? A Systematic Review and Meta-Analysis , 2020, Frontiers in Oncology.

[49]  A. Stenzinger,et al.  Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. , 2020, Cancer discovery.

[50]  Sung-Bae Kim,et al.  Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. , 2020, The Lancet. Oncology.

[51]  H. Iwata,et al.  Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial , 2020, The Lancet.

[52]  Y. Bang,et al.  Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. , 2020, The Lancet. Oncology.

[53]  A. Schneeweiss,et al.  296P Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial , 2020 .

[54]  R. Greil,et al.  LBA13 Tumour infiltrating lymphocytes (TILs), PD-L1 expression and their dynamics in the NeoTRIPaPDL1 trial , 2020 .

[55]  Trevor J Pugh,et al.  Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab , 2020, Nature Cancer.

[56]  F. Bidard,et al.  Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer. , 2020, Clinical chemistry.

[57]  A. Munitz,et al.  A new dawn for eosinophils in the tumour microenvironment , 2020, Nature Reviews Cancer.

[58]  Dong Wang,et al.  An immune-related gene signature for predicting survival and immunotherapy efficacy in hepatocellular carcinoma , 2020, Cancer Immunology, Immunotherapy.

[59]  P. Fasching,et al.  Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  J. Lunceford,et al.  Association of tumor mutational burden (TMB) and clinical outcomes with pembrolizumab (pembro) versus chemotherapy (chemo) in patients with metastatic triple-negative breast cancer (mTNBC) from KEYNOTE-119. , 2020 .

[61]  P. Hegde,et al.  Prevalence Study of PD-L1 SP142 Assay in Metastatic Triple-negative Breast Cancer , 2020, Applied immunohistochemistry & molecular morphology : AIMM.

[62]  M. Tsao,et al.  Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer. , 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[63]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[64]  E. Winer,et al.  Abstract PD5-03: Relationship between tumor-infiltrating lymphocytes (TILs) and outcomes in the KEYNOTE-119 study of pembrolizumab vs chemotherapy for previously treated metastatic triple-negative breast cancer (mTNBC) , 2020 .

[65]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  E. Winer,et al.  Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer , 2020, Clinical Cancer Research.

[67]  P. Yin,et al.  Immune-related gene signature for predicting the prognosis of head and neck squamous cell carcinoma , 2020, Cancer cell international.

[68]  Sang-Hoon Ahn,et al.  PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs , 2020, Cancer research and treatment : official journal of Korean Cancer Association.

[69]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[70]  R. Xu,et al.  Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types. , 2019, JAMA oncology.

[71]  C. Criscitiello,et al.  Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer. , 2019, European journal of cancer.

[72]  K. Pantel,et al.  Liquid biopsy in the era of immune-oncology. Is it ready for prime-time use for cancer patients? , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  O. Cohen,et al.  Prevalence and mutational determinants of high tumor mutation burden in breast cancer , 2019, bioRxiv.

[74]  Chao Li,et al.  “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy , 2019, Modern Pathology.

[75]  K. Weber,et al.  A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[76]  J. Lunceford,et al.  Abstract LB-225: RNA molecular signatures as predictive biomarkers of response to monotherapy pembrolizumab in patients with metastatic triple-negative breast cancer: KEYNOTE-086 , 2019, Clinical Research (Excluding Clinical Trials).

[77]  L. Esserman,et al.  Abstract CT003: Analysis of immune cell infiltrates as predictors of response to the checkpoint inhibitor pembrolizumab in the neoadjuvant I-SPY 2 TRIAL , 2019, Clinical Trials.

[78]  H. Horlings,et al.  Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.

[79]  Benjamin Haibe-Kains,et al.  Spatially distinct tumor immune microenvironments stratify triple-negative breast cancers , 2019, The Journal of clinical investigation.

[80]  A. Giobbie-Hurder,et al.  Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. , 2019, The Lancet. Oncology.

[81]  E. Winer,et al.  Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[82]  S. Loi,et al.  Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[83]  P. Spellman,et al.  Alternative Splicing in Tumors — A Path to Immunogenicity? , 2019, The New England journal of medicine.

[84]  J. Lunceford,et al.  T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[85]  Heikki Joensuu,et al.  Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[87]  T A Chan,et al.  Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[88]  E. Elgabry,et al.  Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study , 2019, JAMA oncology.

[89]  Y. Fujisawa,et al.  Serum Level of Soluble CD163 May Be a Predictive Marker of the Effectiveness of Nivolumab in Patients With Advanced Cutaneous Melanoma , 2018, Front. Oncol..

[90]  L. Pusztai,et al.  Immunological differences between primary and metastatic breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[91]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[92]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[93]  M. J. van de Vijver,et al.  Assessment of PD-L1 expression across breast cancer molecular subtypes, in relation to mutation rate, BRCA1-like status, tumor-infiltrating immune cells and survival , 2018, Oncoimmunology.

[94]  Hui Yu,et al.  PD‐L1 Immunohistochemistry Comparability Study in Real‐Life Clinical Samples: Results of Blueprint Phase 2 Project , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[95]  X. Liu,et al.  Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.

[96]  Jacob Silterra,et al.  Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab , 2018, Nature Medicine.

[97]  A. Gupta,et al.  Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab , 2018, Clinical Cancer Research.

[98]  E. Felip,et al.  Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer , 2018, JAMA oncology.

[99]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[100]  E. V. Van Allen,et al.  Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma , 2018, Journal of Immunotherapy for Cancer.

[101]  K. Flaherty,et al.  Mechanisms of resistance to immune checkpoint inhibitors , 2018, British Journal of Cancer.

[102]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[103]  C. Criscitiello,et al.  Tumor-infiltrating lymphocytes in breast cancer according to tumor subtype: Current state of the art. , 2017, Breast.

[104]  Peter Schmid,et al.  LBA13Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086 , 2017 .

[105]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[106]  E. King,et al.  Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer , 2017, Nature Immunology.

[107]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[108]  E. Jaffee,et al.  Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.

[109]  James D. Brenton,et al.  Liquid biopsies come of age: towards implementation of circulating tumour DNA , 2017, Nature Reviews Cancer.

[110]  F. Hirsch,et al.  PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[111]  N. Taira,et al.  Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer , 2017, Breast Cancer Research and Treatment.

[112]  P. Shah,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis , 2017, Breast Cancer Research.

[113]  S. Ariyan,et al.  Interlesional diversity of T cell receptors in melanoma with immune checkpoints enriched in tissue-resident memory T cells. , 2016, JCI insight.

[114]  P. Forget,et al.  The neutrophil-to-lymphocyte ratio: a narrative review , 2016, Ecancermedicalscience.

[115]  G. Bianchini,et al.  Comparison of tumor‐infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients , 2016, Cancer science.

[116]  S. Adams,et al.  Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. , 2016, JAMA oncology.

[117]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[118]  P. Ascierto,et al.  Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[119]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[120]  L. Pusztai,et al.  New Strategies in Breast Cancer: Immunotherapy , 2016, Clinical Cancer Research.

[121]  T. Fest,et al.  Frequent expression of PD‐L1 on circulating breast cancer cells , 2015, Molecular oncology.

[122]  S. Barni,et al.  Prognostic role of lactate dehydrogenase in solid tumors: A systematic review and meta-analysis of 76 studies , 2015, Acta oncologica.

[123]  B. Nelson,et al.  PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer , 2015, Cancer Immunology Research.

[124]  T. Schumacher,et al.  Neoantigens in cancer immunotherapy , 2015, Science.

[125]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[126]  Carsten Denkert,et al.  Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[127]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[128]  Ben Tran,et al.  Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. , 2014, Journal of the National Cancer Institute.

[129]  L. Gianni,et al.  The immune system and response to HER2-targeted treatment in breast cancer. , 2014, The Lancet. Oncology.

[130]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[131]  E. Mardis,et al.  Cancer Exome Analysis Reveals a T Cell Dependent Mechanism of Cancer Immunoediting , 2012, Nature.

[132]  T. Jacks,et al.  Expression of tumour-specific antigens underlies cancer immunoediting , 2011, Nature.

[133]  V. Bhatt,et al.  Usefulness of the Neutrophil-to-Lymphocyte Ratio in Predicting Short- and Long-Term Mortality in Breast Cancer Patients , 2011, Annals of Surgical Oncology.

[134]  S. Moestrup,et al.  CD163: a regulated hemoglobin scavenger receptor with a role in the anti‐inflammatory response , 2004, Annals of medicine.

[135]  J. Raus,et al.  Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. , 1992, Anticancer research.

[136]  J. Underwood.  Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. , 1974, British Journal of Cancer.